文献速递先天性心脏病外科心外重症与机械循环支持

先天性心脏病患儿植入心室辅助装置的结果:Pedimacs注册分析

Outcomes of children with congenital heart disease implanted with ventricular assist devices: An analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs).
PubMed 文献 · J Heart Lung Transplant · 2018-10-31

基于Pedimacs注册2012年9月至2017年6月471例患儿,108例(24%)为先天性心脏病(CHD),其中双心室45例、单心室63例。CHD患儿6个月死亡率36.4%高于非CHD的12.1%,移植率29.1%低于非CHD的59.9%(p<0.0001)。多变量分析显示CHD是与装置上死亡最强相关因素(HR=2.9,p<0.0001),植入式连续流装置和高容量中心为保护因素。

要点

  • CHD患儿VAD植入后6个月死亡率36.4%,显著高于非CHD患儿的12.1%。
  • CHD患儿6个月移植率29.1%,低于非CHD患儿的59.9%。
  • 植入式连续流装置和高容量中心与更低死亡风险相关。

核心结论

  • CHD患儿使用VAD与非CHD患儿相比死亡风险更高且移植率更低。
  • CHD患儿中接受植入式连续流VAD的亚组生存率更高且与非CHD患儿相当。
  • 经验增加与儿童VAD生存改善相关。

研究设计与样本

  • Pedimacs注册队列研究,纳入2012年9月19日至2017年6月30日登记的患儿。
  • 共471例患儿,其中108例(24%)为CHD,包括双心室45例和单心室63例(1、2或3期)。
  • 比较组间结局,并用多变量分析识别装置上死亡相关因素。

主要发现

  • CHD患儿较非CHD患儿更年轻(5.7±5.7岁 vs 9.8±6.5岁;p<0.0001)且体表面积更小(0.8±0.5 m2 vs 1.2±0.7 m2;p<0.0001)。
  • CHD患儿更常接受体外连续流VAD(36.1% vs 12.9%;p<0.0001),更少接受植入式连续流VAD(27.8% vs 55.0%;p<0.0001)。
  • VAD支持6个月后,CHD患儿死亡率36.4%高于非CHD的12.1%,移植率29.1%低于非CHD的59.9%(p<0.0001)。
  • 多变量分析中CHD是与装置上死亡最强相关因素(HR=2.9;p<0.0001)。
  • 植入式连续流装置(HR=0.3;p<0.0001)和高容量中心(HR=0.6;p=0.02)为保护因素。

临床怎么用

  • CHD患儿VAD植入前应充分评估死亡与移植概率,并知情沟通预后。
  • 在条件允许时优先考虑植入式连续流VAD,可能改善生存。
  • 建议将CHD患儿集中至高容量中心管理以改善结局。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The reported ventricular assist device (VAD) experience in the pediatric congenital heart disease (CHD) population is limited. We sought to describe contemporary use and outcomes of VADs in children with CHD and compare these outcomes to those of non-CHD children. METHODS: Patients enrolled in the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) between September 19, 2012 through June 30, 2017 were included. CHD was classified as biventricular vs single ventricle (Stages 1, 2, or 3). Outcomes were compared between groups and multivariable analysis was used to identify factors associated with mortality on the device. RESULTS: Among the 471 patients enrolled, 108 (24%) had CHD (45 biventricular and 63 single ventricle). CHD patients were younger (5.7 ± 5.7 years vs 9.8 ± 6.5 years; p < 0.0001) and smaller (0.8 ± 0.5 m2 vs 1.2 ± 0.7 m2; p < 0.0001) compared with non-CHD patients. CHD patients were more likely to receive a paracorporeal continuous-flow VAD (36.1% vs 12.9%; p < 0.0001) and less likely to receive an implantable continuous-flow VAD (27.8% vs 55.0%; p < 0.0001) compared with non-CHD patients. After 6 months on a VAD, CHD patients had higher mortality (36.4% vs 12.1%) and a lower transplantation rate (29.1% vs 59.9%) than non-CHD patients (p < 0.0001). In the multivariable analysis, CHD was the factor most strongly associated with mortality on VAD (hazard ratio [HR] = 2.9; p < 0.0001), whereas the factors implantable continuous-flow device and high-volume center were protective (HR = 0.3, p < 0.0001, and HR = 0.6, respectively; p = 0.02). CONCLUSIONS: VAD use in children with CHD is associated with increased mortality and decreased transplant rates compared to children without CHD. For the subgroup of children with CHD who received implantable continuous-flow VADs, survival rates were higher and comparable to those of children without CHD. Increased experience correlated with better survival in pediatric VADs.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Peng DM, Koehl DA, Cantor RS, et al. Outcomes of children with congenital heart disease implanted with ventricular assist devices: An analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs). J Heart Lung Transplant. 2018. PMID: 30459063. doi:10.1016/j.healun.2018.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。